Find trials
Search tips

HTN Management and Cardiovascular Adverse Event Prevention in B-Cell Malignancies Undergoing BTKi

Overview

About this study

The purpose of this study is to prospectively define the incidence of new and/or worsening hypertension in patients with B-cell malignancies on Bruton Tyrosine Kinase Inhibitors.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients with:
    • Chronic lymphocytic leukemia (CLL)[;
    • Mantle cell lymphoma (MCL);
    • Waldenstrom macroglobulinemia (WM);   
    • Mantle cell lymphoma (MCL);
    • marginal zone lymphomas (MZL). 
  • To begin bruton tyrosine kinase inhibitors (BTKi)treatment (either as a single agent or on combination with others), who are willing to return to Mayo Clinic for ongoing follow-up.

Exclusion Criteria:

  • Patients with known CNS involvement of their B cell malignancy.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 7/20/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Joerg Herrmann, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20557235

Mayo Clinic Footer